Program
lurbinectedin
Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.
Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.
Drug pagePM 01183: every studyMany companies study it; this page follows only the 27 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PharmaMarits history only | 202 open or running | phase 3since Apr 10, 2015 | Apr 6, 2009 | Aug 30, 2029phase 3 · NCT06088290 |
| Jazz Pharmaceuticalsits history only | 32 open or running | phase 2since Nov 8, 2021 | Nov 8, 2021 | Jan 28, 2028phase 2 · NCT05734066 |
| Luye Pharma Groupits history only | 21 open or running | phase 3since Jul 3, 2024 | Nov 5, 2020 | Dec 31, 2027phase 3 · NCT06496048 |
| Gilead Sciences | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Rocheits history only | 11 open or running | phase 3since Oct 12, 2021 | Oct 12, 2021 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2025First study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)First studyNCT06801834 · 695 planned · United States, Argentina, Australia and more
Ahead
- Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT06801834
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Oct 2029 | 695 |
How it is read
Names in the registry
- “Lurbinectedin”, 13 entries
- “lurbinectedin (PM01183)”, 6 entries
- “Lurbinectedin (PM01183)”, 3 entries
- “PM01183”, 3 entries
- “Lurbinectedin (regions/countries where approved and available)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Breast Neoplasms, 3 studies
- Neoplasms, 2 studies
- Sarcoma, Ewing, 1 study
- Leiomyosarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.